Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.

@article{Moessner2010IncreasingTE,
  title={Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.},
  author={Ekkehard Moessner and Peter Bruenker and Samuel Moser and Ursula Puentener and Carla Schmidt and Sylvia Herter and Roger Grau and Christian Gerdes and Adam Nopora and Erwin van Puijenbroek and Christina Ferrara and Peter Sondermann and Christiane Jaeger and Pamela Strein and Georg Fertig and Thomas Friess and Christine Schuell and Sabine Bauer and Joseph M. Dal Porto and Christopher Del Nagro and Karim Dabbagh and Martin J S Dyer and Sibrand Poppema and Christian Klein and Pablo Uma{\~n}a},
  journal={Blood},
  year={2010},
  volume={115 22},
  pages={
          4393-402
        }
}
CD20 is an important target for the treatment of B-cell malignancies, including non-Hodgkin lymphoma as well as autoimmune disorders. B-cell depletion therapy using monoclonal antibodies against CD20, such as rituximab, has revolutionized the treatment of these disorders, greatly improving overall survival in patients. Here, we report the development of GA101 as the first Fc-engineered, type II humanized IgG1 antibody against CD20. Relative to rituximab, GA101 has increased direct and immune… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 313 CITATIONS, ESTIMATED 54% COVERAGE

Anti-CD20 monoclonal antibodies: reviewing a revolution

  • Human vaccines & immunotherapeutics
  • 2018
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Hypersensitivity Reactions to Obinutuzumab in Cynomolgus Monkeys and Relevance to Humans.

  • Toxicologic pathology
  • 2017
VIEW 13 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy

  • Drug design, development and therapy
  • 2017
VIEW 4 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED

Obinutuzumab: what is there to learn from clinical trials?

VIEW 5 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Use of polyclonal/monoclonal antibody therapies in transplantation.

  • Expert opinion on biological therapy
  • 2017
VIEW 10 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2010
2019

CITATION STATISTICS

  • 47 Highly Influenced Citations

  • Averaged 30 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 38 REFERENCES

Glycoengi neered therapeutic antibodies

P Brunker, P Sondermann, P. Umana
  • 2009

Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

P Umana, J Jean-Mairet, JE Bailey, MS. Bailey
  • U.S. Patent
  • 2009

Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009